SIRT1 suppresses cellular accumulation of β-TrCP E3 ligase via protein degradation

Biochemical and Biophysical Research Communications

Volumn 441, Issue 4, 2013, Pages 831-837

  Woo, Seon Rang ^a   Byun, Jae Gwang ^b   Kim, Yang Hyun ^a   Park, Eun Ran ^a   Joo, Hyun Yoo ^a   Yun, Miyong ^a   Shin, Hyun Jin ^a   Kim, Su Hyeon ^a   Shen, Yan Nan ^a   Park, Jeong Eun ^a   Park, Gil Hong ^b   Lee, Kee Ho ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

TrCP; Nucleus; Post translational degradation; Pyruvate; Resveratrol; SIRT1

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; MESSENGER RNA; RESVERATROL; SIRTUIN 1;

ARTICLE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS; TRANSCRIPTION INITIATION;

NUCLEUS; POST-TRANSLATIONAL DEGRADATION; PYRUVATE; RESVERATROL; SIRT1; Β-TRCP;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; GLUCOSE; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN BIOSYNTHESIS; PROTEOLYSIS; RNA, MESSENGER; SIRTUIN 1; STILBENES; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES;

EID: 84888855962     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.146     Document Type: Article

References (33)

1. Fuchs S.Y., Spiegelman V.S., Kumar K.G. The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004, 23:2028-2036.
2. Freccas D., Paqano M. Deregulated proteolysis by the F-box protein SKP2 and beta-TCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
3. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 1:9-20.
4. Spiegelman V.S., Tang W., Chan A.M., Igarashi M., Aaronson S.A., Sassoon D.A., Katoh M., Slaga T.J., Fuchs S.Y. Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J. Biol. Chem. 2002, 277:36624-36630.
5. Spiegelman V.S., Slaga T.J., Pagano M., Minamoto T., Ronai Z., Fuchs S.Y. Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol. Cell 2000, 5:877-882.
6. Spiegelman V.S., Tang W., Katoh M., Slaga T.J., Fuchs S.Y. Inhibition of HOS expression and activities by Wnt pathway. Oncogene 2002, 21:856-860.
7. Spiegelman V.S., Stavropoulos P., Latres E., Pagano M., Ronai Z., Slaga T.J., Fuchs S.Y. Induction of beta-transducin repeat-containing protein by JNK signaling and its role in the activation of NF-kappaB. J. Biol. Chem. 2001, 276:27152-27158.
8. Liu J., Suresh Kumar K.G., Yu D., Molton S.A., McMahon M., Herlyn M., Thomas-Tikhonenko A., Fuchs S.Y. Ocogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene 2007, 26:1954-1958.
9. Wei S., Chuang H.C., Tsai W.C., Yang H.C., Ho S.R., Paterson A.J., Kulp S.K., Chen C.S. Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein. Mol. Pharmacol. 2009, 76:47-57.
10. Wei S., Lin L.F., Yang C.C., Wang Y.C., Chang G.D., Chen H., Chen C.S. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. Mol. Pharmacol. 2007, 72:725-733.
11. Wei S., Kulp S.K., Chen C.S. Energy restriction as an antitumor target of thiazolidinediones. J. Biol. Chem. 2010, 285:9780-9791.
12. Knutson M.D., Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr. Rev. 2008, 66:591-596.
13. Gertz M., Nquyen G.T., Fischer F., Suenkel B., Schlicker C., Franzel B., Tomaschewski J., Aladini F., Becher C., Wolters D., Steeqbern C. A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One 2012, 11:e49761.
14. Beher D., Wu J., Cumine S., Kim K.W., Lu S.C., Stangan L., Wang M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 2009, 74:619-624.
15. BJorklund M., Roos J., Goqvadze V., Shoshan M. Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother. Pharmacol. 2011, 68:1459-1467.
16. Frazzi R., Valli R., Tamaqnini I., Casali B., Latruffe N., Merli F. Resveratrol-mediated apoptosis of Hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. Int. J. Cancer 2013, 132:1013-1021.
17. Annabi B., Lord-Dufour S., Vézina A., Béliveau R. Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is Sirt1-independent. Drug Target Insights 2012, 6:1-11.
18. Centeno-Baez C., Dallaire P., Marette A. Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E922-E930.
19. Kitada M., Kume S., Imaizumi N., Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011, 60:634-643.
20. Lan D., Lu M., Sharma S., Mellon P.L., Olefsky J.M., Webster N.J. Trans-resveratrol inhibits phosphorylation of Smad2/3 and represses FSHβ gene expression by a SirT1-independent pathway in LβT2 gonadotrope cells. Reprod. Toxicol. 2011, 32:85-92.
21. Mader I., Wabitsch M., Debatin K.M., Fischer-Posovszky P., Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 2010, 24:1997-2009.
22. Vaziri H., Dessain S.K., Eaton E.N., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
23. Jeong J., Juhn K., Lee H., Kim S.H., Min B.H., Lee K.M., Cho M.H., Park G.H., Lee K.H. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp. Mol. Med. 2007, 39:8-13.
24. Yuan Z., Zhang X., Sengupta N., Lane W.S., Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol. Cell 2007, 27:149-162.
25. Chen W.Y., Wang D.H., Yen R.W.C., Luo J., Gu W., Stephen B. Baylin tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123:437-448.
26. Joo H.Y., Woo S.R., Shen Y.N., Yun M.Y., Shin H.J., Park E.R., Kim S.H., Park J.E., Ju Y.J., Hong S.H., Hwang S.G., Cho M.K.H., Kim J., Lee K.H. SIRT1 interacts with and protects glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from nuclear translocation: implications for cell survival after irradiation. Biochem. Biophys. Res. Commun. 2012, 424:681-686.
27. North B.J., Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 2004, 5:224.
28. Chu F., Chou P.M., Zheng X., Mirkin B.L., Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 2005, 65:10183-10187.
29. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
30. Wang Z., Chen W. Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer 2013, 4:82-90.
31. Palacios J.A., Herranz D., De Bonis M.L., Velasco S., Serrano M., Blasco M.A. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J. Cell Biol. 2010, 191:1299-1313.
32. Ju Y.J., Shin H.J., Park J.E., Juhn K.M., Woo S.R., Kim H.Y., Han Y.H., Hwang S.G., Hong S.H., Kang C.M., Yoo Y.D., Park W.B., Cho M.H., Park G.H., Lee K.H. Clonal cell populations unresponsive to radiosensitization induced by telomerase inhibition. Biochem. Biophys. Res. Commun. 2010, 402:198-202.
33. Davis M., Hatzubai A., Andersen J.S., Ben-Shushan E., Fisher G.Z., Yaron A., Bauskin A., Mercurio F., Mann M., Ben-Neriah Y. Pseudosubstrate regulation of the SCF(beta-TrCP) ubiquitin ligase by hnRNA-U. Genes Dev. 2002, 16:439-451.